Ending the Diagnostic Odyssey Act of 2021

Senate Bill 2022 - Ending the Diagnostic Odyssey Act of 2021: Overview, Status, and Impact

Hozzl · 2022-12-31T05:28:21Z

Explore the details of Senate Bill 2022 Ending the Diagnostic Odyssey Act of 2021 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/31/2022, 5:28 AM

Congressional Summary of S 2022

Ending the Diagnostic Odyssey Act of 2021

This bill allows state Medicaid programs to cover whole genome sequencing services for certain individuals.

Specifically, states may cover such services for individuals under the age of 21 (or a lower age, if the state chooses) and for former foster youth under the age of 26 who (1) have been referred or admitted to an intensive care unit or seen by a medical specialist for a suspected genetic or undiagnosed disease, or (2) are suspected by a medical specialist to have a neonatal- or pediatric-onset genetic disease.

The Centers for Medicare & Medicaid Services may award grants to assist states in developing plans to cover such services.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 2022

Bill S 2022 is currently in the status of Bill Introduced since June 10, 2021. Bill S 2022 was introduced during Congress 117 and was introduced to the Senate on June 10, 2021. Bill S 2022's most recent activity was Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4046-4047) as of June 10, 2021

Bipartisan Support of Bill S 2022

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 2022

Primary Policy Focus

Health

Potential Impact Areas

- Adoption and foster care

- Cell biology and embryology

- Child health

- Emergency medical services and trauma care

- Genetics

- Health care costs and insurance

- Health care coverage and access

- Health care quality

- Health programs administration and funding

- Health technology, devices, supplies

- Hospital care

- Medicaid

- Medical tests and diagnostic methods

- State and local government operations

Alternate Title(s) of Bill S 2022

A bill to enable States to better provide access to whole genome sequencing clinical services for certain undiagnosed children under the Medicaid program, and for other purposes.

Ending the Diagnostic Odyssey Act of 2021